We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
TIDMEVG
Evgen Pharma PLC
21 June 2017
Hardman Research: Making clinical progress
Making clinical progress: Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen's proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. The results presentation is a good opportunity for Evgen to present the progress of its clinical pipeline. SFX-01 is progressing in two Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/20.06.17-making-clinical-progress.pdf
To contact us: Analysts: Hardman & Co Dr Martin Hall mh@hardmanandco.com 35 New Broad Street Dr Dorothea Hill dmh@hardmanandco.com London Dr Gregoire Pave gp@hardmanabdco.com EC2M 1NH Telephone: +44 20 7194 7622 Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUPCQUPMGMU
(END) Dow Jones Newswires
June 21, 2017 02:15 ET (06:15 GMT)
1 Year Evgen Pharma Chart |
1 Month Evgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions